Thomson Reuters

Supported by an independent educational grant from Astellas

Access Dermatology

Advisory Board
About Us
Contact Us

Breaking News
Clinical Trials
Congress Reports
Clinical Cases
Core Papers
Expert Interviews
Editorial Blog
Who's Who
Centre of Learning Excellence
Image Bank
Professional Development
Calendar
Useful Links

Thomson Reuters

Clinical Trials

Home »
Clinical Trials »
Infliximab in psoriasis: The EXPRESS II...

Infliximab in psoriasis: The EXPRESS II (Evaluation of Infliximab for Psoriasis Efficacy and Safety Study)

Infliximab for the treatment of moderate to severe psoriasis: Response to retreatment after 16 weeks or more between infusions

to Continue Reading, Login Now

Please Login

User ID Password

Remember Me

If you are a registered user but you have forgotten your password, please click here

If you are not a registered user, please register here

Last updated: 12 December 2010

AccessDermatology | © Copyright 2010 Prous Science S.A.U. a Thomson Reuters business or its licensors. All rights reserved. Legal Information. Send your comments to Webmaster
ISSN 2013-8202

This site complies with the HONcode standard for trustworthy health information:
verify here.